Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

• George S. Laszlo,
• Todd A. Alonzo,
• Chelsea J. Gudgeon,
• Kimberly H. Harrington,
• Alex Kentsis,
• Robert B. Gerbing,
• Yi-Cheng Wang,
• Rhonda E. Ries,
• Susana C. Raimondi,
• Betsy A. Hirsch,
• Alan S. Gamis,
• Soheil Meshinchi,
• Roland B. Walter

Affiliations

George S. Laszlo

Clinical Research Division, Fred Hutchinson Cancer Research Center

Todd A. Alonzo

Department of Biostatistics, University of Southern California

Chelsea J. Gudgeon

Clinical Research Division, Fred Hutchinson Cancer Research Center

Kimberly H. Harrington

Clinical Research Division, Fred Hutchinson Cancer Research Center

Alex Kentsis

Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute

Robert B. Gerbing

Children’s Oncology Group

Yi-Cheng Wang

Children’s Oncology Group

Rhonda E. Ries

Clinical Research Division, Fred Hutchinson Cancer Research Center

Susana C. Raimondi

Children’s Oncology Group

Betsy A. Hirsch

Children’s Oncology Group

Alan S. Gamis

Children’s Oncology Group

Soheil Meshinchi

Clinical Research Division, Fred Hutchinson Cancer Research Center

Roland B. Walter

Clinical Research Division, Fred Hutchinson Cancer Research Center